Education
About Us
Working with TipRanks
Follow Us
Imunon (IMNN)
NASDAQ:IMNN
IMNN Stock Chart & Stats
$3.86
-$0.06(-6.43%)
At close: 4:00 PM EST
$3.86
-$0.06(-6.43%)
Day’s Range― - ―
52-Week Range$3.56 - $41.22
Previous CloseN/A
Volume151.93K
Average Volume (3M)131.31K
Market Cap
$9.72M
Enterprise Value$11.79M
Total Cash (Recent Filing)$5.25M
Total Debt (Recent Filing)$1.10M
Price to Earnings (P/E)―
Beta-0.61
Next Earnings
Mar 26, 2026EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.16
Shares Outstanding2,521,206
10 Day Avg. Volume100,527
30 Day Avg. Volume131,312
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.96
Price to Sales (P/S)0.00
P/FCF Ratio-0.67
Enterprise Value/Market Cap1.21
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.43
Enterprise Value/Ebitda-0.85
Forecast
1Y Price Target
$12.00Price Target Upside210.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory AdvantagesIMNN-001 has orphan status in the US and EU, providing regulatory benefits and market exclusivity.
Strategic FinancingImunon has secured near-term financing through a private placement, providing essential capital needed to cover initiation-related costs of the OVATION study.
Therapeutic EfficacyIMNN-001 therapy led to consistent and clinically meaningful improvements in key endpoints across treatment groups, including a 13-month increase in overall survival and a 3-month increase in progression-free survival compared to standard care.
Bears Say
Funding ChallengesThe company is in active discussions with potential partners to secure essential capital for the Phase 3 OVATION 3 study.
Regulatory RiskThe trial's design includes interim analyses which could lead to an earlier active readout, potentially accelerating the approval process.
Trial ComplexityAdditional trial sites are expected to activate shortly, with an estimated total of ~45 sites, indicating a broad and robust study.
Imunon News
IMNN FAQ
What was Imunon’s price range in the past 12 months?
Imunon lowest stock price was $3.56 and its highest was $41.22 in the past 12 months.
What is Imunon’s market cap?
Imunon’s market cap is $9.72M.
When is Imunon’s upcoming earnings report date?
Imunon’s upcoming earnings report date is Mar 26, 2026 which is in 118 days.
How were Imunon’s earnings last quarter?
Imunon released its earnings results on Nov 13, 2025. The company reported -$1.16 earnings per share for the quarter, beating the consensus estimate of -$1.199 by $0.039.
Is Imunon overvalued?
According to Wall Street analysts Imunon’s price is currently Undervalued.
Does Imunon pay dividends?
Imunon does not currently pay dividends.
What is Imunon’s EPS estimate?
Imunon’s EPS estimate is -0.79.
How many shares outstanding does Imunon have?
Imunon has 2,521,206 shares outstanding.
What happened to Imunon’s price movement after its last earnings report?
Imunon reported an EPS of -$1.16 in its last earnings report, beating expectations of -$1.199. Following the earnings report the stock price went up 5.316%.
Which hedge fund is a major shareholder of Imunon?
Currently, no hedge funds are holding shares in IMNN
Company Description
Imunon
Imunon, Inc. (IMNN) is a biotechnology company focused on the development and commercialization of innovative therapies that leverage its proprietary platform technologies. The company's primary areas of focus include oncology and infectious diseases, with a core emphasis on developing advanced DNA-based immunotherapies and vaccine solutions. Imunon aims to address unmet medical needs by providing effective and safe treatment options for patients worldwide.
IMNN Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call painted a positive picture with significant progress in clinical trials and strategic planning. Despite financial constraints, the company has managed to achieve regulatory endorsements and reduce operating costs significantly. The successful engagement with the scientific community and regulatory bodies adds to the optimistic outlook, although financial limitations remain a concern.View all IMNN earnings summariesIMNN Stock 12 Month Forecast
Average Price Target
$12.00
▲(210.88% Upside)
Technical Analysis
Kazia Therapeutics
―
Phio Pharmaceuticals
―
Genprex
―
Galecto
―
TransCode Therapeutics
―
Ownership Overview
12.23% Insiders
0.31% Mutual Funds
2.91% Other Institutional Investors
84.23% Public Companies and Individual Investors
Options Prices
Currently, No data available
---